XML 63 R53.htm IDEA: XBRL DOCUMENT v3.22.4
DEFERRED REVENUE (Details Narrative) - USD ($)
9 Months Ended
Dec. 31, 2022
Mar. 31, 2022
Defined Benefit Plan Disclosure [Line Items]    
Deferred revenues $ 35,556 $ 45,559
Deferred revenues current component 13,333 13,333
Deferred revenues long-term component 22,223 $ 32,226
TAGI Pharma [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Unamortized amount $ 200,000  
Licensing agreement beginning Sep. 30, 2010  
Licensing agreement ending Aug. 31, 2025